Clinical trials: Acute Sinusitis
Sinusitis, Sinusitis, Acute
Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.
The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.
- Conditions
- Sinusitis, Sinusitis, Acute, Rhinosinusitis, Rhinosinusitis Acute
- Trial name
- NCT03729258
- Testing
- Infex 400 MR, Infex 200 IR
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Anti-Infective Agents
Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
The objective of this study is to assess the efficacy and safety of Avelox Tablet 400 mg (hereinafter as "Avelox") in treating secondary infection of chronic respiratory disease.It is a local prospective and observational study…
- Trial name
- NCT01690533
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- Japan
- Volunteers
- 497 people
- Sponsor
- Bayer
Recurrent Acute Rhinosinusitis
Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis
A two-week therapy of nitric oxide nasal spray (NONS) vs Placebo (saline nasal spray) initiated immediately after the onset of a new Recurrent Acute Rhinosinusitis (RARS) episode to assess the acceleration to clinical success…
- Trial name
- NONS-RARS-01 (NCT06264141)
- Testing
- Nitric Oxide Releasing Solution, Nasal spray with isotonic saline
- Where
- 7 sites in Canada
- Volunteers
- 162 people
- Sponsor
- Sanotize Research and Development corp.
Acute Bacterial Sinusitis (ABS)
Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis
To compare the safety/tolerability and efficacy of a 14-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 14-day course of amoxicillin-clavulanate tablets (875/125 mg BID) for the treatment of…
- Trial name
- NCT00644553
- Testing
- Clarithromycin, Amoxicillin
- Where
- 53 sites in United States, Canada and 7 more
- Volunteers
- 437 people
- Sponsor
- Abbott
Acute Rhinosinusitis
Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis
Study to verify the efficacy and tolerability of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute, uncomplicated rhinosinusitis (inflammation of the nasal and paranasal sinuses).
- Trial name
- CESAR (NCT02296814)
- Testing
- Sinusitis Hevert SL Tablet
- Where
- 20 sites in Germany
- Volunteers
- 314 people
- Sponsor
- Hevert-Arzneimittel GmbH & Co. KG
Sinusitis, Bacterial Infections
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis
- Trial name
- NCT00493038
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin/Clavulanate
- Where
- 34 sites in Italy
- Volunteers
- 293 people
- Sponsor
- Bayer
Nasal Obstruction, Common Cold
Observational Study of RHINOSEDAL in Acute Nasal Obstruction
This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction…
- Conditions
- Nasal Obstruction, Common Cold, Allergic Rhinitis, Non-allergic Rhinitis
- Trial name
- RHINOSEDAL (NCT07620522)
- Testing
- RHINOSEDAL
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Laboratoires Elerte
Acute Respiratory Infection, Bronchitis
Phase 4 Study - Mucinex D as Adjunct Therapy
The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.
- Conditions
- Acute Respiratory Infection, Bronchitis, Rhinosinusitis
- Trial name
- NCT00441246
- Testing
- Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)
- Where
- 28 sites in United States
- Volunteers
- 600 people
- Sponsor
- Adams Respiratory Therapeutics
Acute Rhinitis, Nasal Obstruction
Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction
The purpose of this post-market clinical investigation is to assess the performance and the safety of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert.
- Conditions
- Acute Rhinitis, Nasal Obstruction, Rhinosinusitis, Rhinopharyngitis
- Trial name
- DEMECA (NCT06580210)
- Where
- 3 sites in France
- Volunteers
- 114 people
- Sponsor
- Laboratoires Gilbert
Rhinosinusitis
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
The trial was conducted as a prospective, randomized, multinational, multicenter, double-blind study in 4 parallel groups of patients.
- Trial name
- NCT04123405
- Testing
- acetylcysteine
- Where
- 37 sites in Bulgaria, Germany and 2 more
- Volunteers
- 944 people
- Sponsor
- Sandoz
Acute Bacterial Sinusitis
Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis
To compare the safety and efficacy of a ten-day course of therapy of cefdinir, 600 mg QD, to a ten-day course of therapy of levofloxacin, 500 mg QD, in the treatment of acute bacterial sinusitis.
- Trial name
- NCT00645073
- Testing
- cefdinir (Omnicef), levofloxacin
- Where
- 33 sites in United States, Poland
- Volunteers
- 271 people
- Sponsor
- Abbott
Sinusitis
BAY12-8039: 5 Days for Sinusitis vs Placebo
The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief.
- Trial name
- NCT00492024
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 51 sites in United States
- Volunteers
- 374 people
- Sponsor
- Bayer
Sinusitis
Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis
This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin® Rhinitis Nasal Spray.
- Trial name
- SNS01 (NCT01684540)
- Testing
- Medical Device, Drug-like, Sinupret forte
- Where
- 6 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Bitop AG
Common Cold
Testing the Efficacy in Adults With Cold of HEalsea Rescue*
Healsea® Rescue* is a CE-marked class I medical device. This is a saline-based nasal spray supplemented with a natural Symbiofilm™ extract (0.04%) isolated from the marine bacteria.
- Trial name
- TEACHER (NCT05819190)
- Testing
- Healsea Rescue*
- Where
- Bulgaria
- Volunteers
- 200 people
- Sponsor
- Lallemand Pharma AG
Recurrent Acute Rhinosinusitis
Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)
This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
- Trial name
- CABERNET (NCT01714687)
- Testing
- balloon sinus dilation, medical therapy
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- Integra LifeSciences Corporation
Sinusitis Bacterial
Point-of-Care Immunoassay for Detection of Bacterial Sinusitis
This study is conducted to evaluate the performance of a rapid, point-of-care in vitro diagnostic device (Sinu-Test®) for the qualitative detection of the three most common pathogens responsible for causing bacterial sinusitis.
- Trial name
- NCT03584737
- Testing
- rapid in vitro diagnostic test, bacterial culture, PCR assay
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- ENTvantage Dx
Sinusitis, Maxillary Sinusitis
A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses
The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with amoxicillin/clavulanate potassium in the treatment of adults with rapid onset of severe inflammation/infection of…
- Trial name
- NCT00249210
- Testing
- levofloxacin
- Volunteers
- 614 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sinusitis, Acute
Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
Acute Bacterial Rhinosinusitis (ABRS) is a respiratory inflammation commonly seen in clinical practice, which has with respiratory symptoms including nasal congestion, rhinorrhoea, postnasal discharge and cough and is associated…
- Trial name
- NCT01934231
- Testing
- Amoxicillin-Potassium Clavulanate Combination
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Maxillary Sinusitis
Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis
The purpose of this study is to compare compliance between patients with Acute Bacterial Sinusitis (ABS) treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the…
- Trial name
- EASY (NCT01032174)
- Testing
- Azithromycin SR, Amoxiclav 1000 mg
- Volunteers
- 123 people
- Sponsor
- Pfizer
Acute Bacterial Sinusitis
Treatment of Patients With Acute Sinusitis
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
- Trial name
- NCT00930488
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 19 sites in Austria, Bahrain and 17 more
- Volunteers
- 6,777 people
- Sponsor
- Bayer